v3.25.1
Share-Based Compensation
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Share-Based Compensation [Abstract]    
Share-Based Compensation
14.Share-Based Compensation

 

2024 Equity Incentive Plan

 

The Company’s 2024 Equity Incentive Plan (the “2024 Plan”) became effective at the Closing Date. As of March 31, 2025, 6,240,773 shares of common stock were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024 Plan reserve will automatically increase in an amount equal to the lesser of (a) 5% of the number of shares of the Company’s common stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company’s board of directors.

 

Under the 2024 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through March 31, 2025, the Company has not granted any awards under the 2024 Plan.

 

2014 Stock Incentive Plan

 

The 2014 Stock Incentive Plan (the “2014 Plan”) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration, no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger, which totaled 5,005,748 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically vest over four years. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term of the stock options is ten years.

 

Stock Options

 

The summary of the Company’s stock option activity is as follows:

 

   

Number of

Stock

Options

   

Weighted-
Average

Exercise Price

   

Weighted-
Average

Remaining

Contractual Life

 
Outstanding at December 31, 2024     9,881,842     $ 1.71       5.4  
Granted                  
Exercised                  
Forfeited/Expired/Cancelled     (2,929,108 )   $ 1.66        
Outstanding at March 31, 2025     6,952,734     $ 1.73       4.9  
Exercisable at March 31, 2025     5,758,095     $ 1.74       5.0  

 

Restricted Stock Units

 

The Company granted restricted stock units (“RSUs”) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.

The summary of the Company’s restricted stock unit activity is as follows:

 

      Number
of
Shares
    Weighted-
Average
Grant Date
Fair Value
    Weighted-
Average
Remaining
Vesting Period
 
Outstanding at December 31, 2024       22,156     $ 1.63       0.2  
Granted                    
Vested       (16,617 )     1.63        
Forfeited                    
Outstanding at March 31, 2025       5,539     $ 1.63        

 

During the three months ended March 31, 2025, 16,617 RSUs vested in accordance with their terms, but the shares of common stock were not issued to the holders as of March 31, 2025.

 

On October 22, 2024, the Company’s board of directors authorized the issuance of 300,000 RSUs (or approximately 613,467 RSUs as adjusted for the Merger closing based on the Exchange Ratio), that were not yet issued as of March 31, 2025. For the three months ended March 31, 2025, the Company recorded $204 in stock compensation expense related to these authorized RSUs. The total accrued expenses related to these authorized RSUs were $598 and $394 as of March 31, 2025 and December 31, 2024, respectively.

 

Stock-Based Compensation Expense

 

The summary of the recorded stock-based compensation expense is as follows:

 

    Three months ended March 31,  
    2025     2024  
             
Research and development   $ 10     $ 26  
General and administrative     502       537  
Total stock-based compensation   $ 512     $ 563  

 

As of March 31, 2025, there was approximately $515 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over a weighted-average period of 0.9 years. As of March 31, 2025, there was approximately $4 of unrecognized compensation cost related to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 0.1 years.

15.Share-Based Compensation

 

2024 Equity Incentive Plan

 

The Company’s 2024 Equity Incentive Plan (the “2024 Plan”) became effective at the Closing Date. As of December 31, 2024, 6,240,773 shares of common stock were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024 Plan reserve will automatically increase in an amount equal to the lesser of (a) 5% of the number of shares of the Company’s common stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company’s board of directors.

 

Under the 2024 Plan, the Company can grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through December 31, 2024, the Company has not granted any awards under the 2024 Plan.

 

2014 Stock Incentive Plan

 

The 2014 Stock Incentive Plan (the “2014 Plan”) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration, no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger, which totaled 5,005,748 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically vest over four years. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term of the stock options is ten years.

 

Stock Options

 

The summary of the Company’s stock option activity is as follows:

 

    Number of
Stock
Options
    Weighted-
Average
Exercise
Price
    Weighted-
Average
Remaining
Contractual
Life
 
Outstanding at December 31, 2023     11,072,767     $ 1.64       6.1  
Granted    
-
     
-
      -  
Exercised    
-
     
-
      -  
Forfeited/Expired/Cancelled     (1,190,925 )   $ 1.01       -  
Outstanding at December 31, 2024     9,881,842     $ 1.71       5.4  
Exercisable at December 31, 2024     8,281,791     $ 1.71       5.4  

Stock Option Valuation

 

The assumptions that the Company used to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:

 

   Year ended
December 31,
2023
 
Risk-free interest rate   3.53%
Expected term (in years)   6.3 
Expected volatility   71%
Expected dividend yield   0%

 

The weighted average grant date fair value of awards granted during the year ended December 31, 2023, was $4.26 per share.

 

No stock options were granted during the year ended December 31, 2024.

 

Restricted Stock Units

 

The Company granted restricted stock units (“RSUs”) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.

 

The summary of the Company’s restricted stock unit activity is as follows:

 

   Number of
Shares
   Weighted-
Average
Grant Date
Fair Value
   Weighted-
Average
Remaining
Vesting Period
 
Outstanding at December 31, 2023   93,728   $1.63    1.2 
Granted   
-
    
-
    - 
Vested   (71,571)   1.63    - 
Forfeited   
-
    
-
    - 
Outstanding at December 31, 2024   22,156   $1.63    0.2 

 

In November and December 2024, after the Closing Date, 11,073 RSUs vested in accordance with their terms, but the shares of New Abpro common stock were not issued to the holders as of December 31, 2024.

 

On October 22, 2024, the Company’s board of directors authorized the issuance of 300,000 RSUs (or approximately 613,467 RSUs as adjusted for the Merger closing based on the Exchange Ratio), that were not yet issued as of December 31, 2024. The Company recorded the fair value of these RSUs, totaling $394, in accrued expenses as of December 31, 2024.

 

Stock-Based Compensation Expense

 

The summary of the recorded stock-based compensation expense is as follows:

 

   Years ended December 31, 
   2024   2023 
         
Research and development  $72   $118 
General and administrative   1,855    2,187 
Total stock-based compensation  $1,927   $2,305 

 

As of December 31, 2024, there was approximately $1,302 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over a weighted-average period of 1.1 years. As of December 31, 2024, there was approximately $31 of unrecognized compensation cost related to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 0.3 years.